Sponsors Show Major Improvement in Investigative Site Relationships
In a recent CenterWatch survey, investigative sites rated sponsor companies on more than 36 individual relationship attributes.
In a recent CenterWatch survey, investigative sites rated sponsor companies on more than 36 individual relationship attributes. The top five highest-rated large sponsors-those with 2013 total revenue from drug sales greater than $11 billion-were Novo Nordisk, Takeda, GlaxoSmithKline, AstraZeneca and Janssen. The top five mid-sized and small sponsors-with 2013 total revenue from drug sales less than $11 billion-were Servier, Celgene, Biogen Idec, Otsuka and Forest Laboratories (acquired by Actavis last year). This survey also marks one of the few times in almost 20 years that strong improvement was observed in sponsors narrowing their performance gaps across attributes that sites rate as most important in defining relationship effectiveness.
Relationship attributes that sites rate as most important in defining relationship effectiveness include quality of monitors, study support and easily accessible staff to resolve problems.With the current industry-wide focus on patient centric clinical trials, sponsors have invested more time and resources in their investigative site relationships with the ultimate goal to better engage and enhance study volunteer participation experiences. To achieve this goal, sponsors have implemented a number of initiatives to reduce protocol complexity and improve study feasibility, efficiency and convenience.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
